Allergan has entered into a definitive agreement to acquire all outstanding shares and assets of privately owned dermatology company Vicept Therapeutics. Vicept’s lead investigational product, V-101, is a topical cream for the treatment of erythema associated with rosacea. It has achieved positive results in two randomized, placebo-controlled Phase II studies. The acquisition agreement includes a $75 million cash upfront payment by Allergan, plus up to an aggregate of $200 million in payments contingent upon achieving certain future development and regulatory milestones.
Allergan Takes on New Rosacea Topical
Aug 18th, 2011